BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1089 related articles for article (PubMed ID: 18824005)

  • 1. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP; Bryson S; Nieva JL; Pai EF
    J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
    Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
    J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
    Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.
    Menendez A; Chow KC; Pan OC; Scott JK
    J Mol Biol; 2004 Apr; 338(2):311-27. PubMed ID: 15066434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
    Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5.
    de la Arada I; Julien JP; de la Torre BG; Huarte N; Andreu D; Pai EF; Arrondo JL; Nieva JL
    J Phys Chem B; 2009 Oct; 113(41):13626-37. PubMed ID: 19754136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.
    McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ
    Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of interaction between the HIV-1-neutralizing monoclonal antibody 2F5 and its epitope.
    Fiebig U; Schmolke M; Eschricht M; Kurth R; Denner J
    AIDS; 2009 May; 23(8):887-95. PubMed ID: 19414989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a trimeric MPER containing HIV-1 gp41 antigen.
    Hinz A; Schoehn G; Quendler H; Hulsik DL; Stiegler G; Katinger H; Seaman MS; Montefiori D; Weissenhorn W
    Virology; 2009 Aug; 390(2):221-7. PubMed ID: 19539967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody.
    Sánchez-Martínez S; Lorizate M; Hermann K; Kunert R; Basañez G; Nieva JL
    FEBS Lett; 2006 Apr; 580(9):2395-99. PubMed ID: 16616522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.
    Cardoso RM; Zwick MB; Stanfield RL; Kunert R; Binley JM; Katinger H; Burton DR; Wilson IA
    Immunity; 2005 Feb; 22(2):163-73. PubMed ID: 15723805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.
    Ofek G; Zirkle B; Yang Y; Zhu Z; McKee K; Zhang B; Chuang GY; Georgiev IS; O'Dell S; Doria-Rose N; Mascola JR; Dimitrov DS; Kwong PD
    J Virol; 2014 Mar; 88(5):2426-41. PubMed ID: 24335316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.
    Ou W; Lu N; Yu SS; Silver J
    J Virol; 2006 Mar; 80(5):2539-47. PubMed ID: 16474160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    Ofek G; Tang M; Sambor A; Katinger H; Mascola JR; Wyatt R; Kwong PD
    J Virol; 2004 Oct; 78(19):10724-37. PubMed ID: 15367639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Construction of peptide mimetics of an epitope of the human immunodeficiency virus (HIV-1) gp41 protein, recognized by virus-neutralizing antibodies 2F5].
    Tumanova OIu; Kuvshinov VN; Azaev MSh; Masharskiĭ AE; Klimov NA; Kozlov AP; Il'ichev AA; Sandakhchiev LS
    Mol Biol (Mosk); 2001; 35(1):146-51. PubMed ID: 11234374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody.
    Luftig MA; Mattu M; Di Giovine P; Geleziunas R; Hrin R; Barbato G; Bianchi E; Miller MD; Pessi A; Carfí A
    Nat Struct Mol Biol; 2006 Aug; 13(8):740-7. PubMed ID: 16862157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10.
    Cardoso RM; Brunel FM; Ferguson S; Zwick M; Burton DR; Dawson PE; Wilson IA
    J Mol Biol; 2007 Feb; 365(5):1533-44. PubMed ID: 17125793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
    Guenaga J; Wyatt RT
    PLoS Pathog; 2012; 8(7):e1002806. PubMed ID: 22829767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
    Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
    J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.
    Zwick MB; Komori HK; Stanfield RL; Church S; Wang M; Parren PW; Kunert R; Katinger H; Wilson IA; Burton DR
    J Virol; 2004 Mar; 78(6):3155-61. PubMed ID: 14990736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.